Fisher & Paykel Healthcare dodges worst of US tariff risk: Jarden

Fisher & Paykel Healthcare dodges worst of US tariff risk: Jarden
About 43% of Fisher & Paykel Healthcare’s revenue comes from the US. (Image: Supplied)
John Anthony
Jarden has raised its rating and target share price for Fisher & Paykel Healthcare by 10%, as Thursday’s US tariff announcements proved less damaging than expected.Following US President Donald Trump’s unveiling of “Liberation Day” tariffs, shares in Fisher & Paykel Healthcare (FPH), a company with significant export exposure to the US, traded as low as $32.60 in the wake of the announcement on Thursday. They were currently at $34.80.In a research note released late Thursday evening, Jarden analysts Adrian Allbon...

More Economy

Cost-benefit issues in spotlight amid RBNZ review
Finance

Cost-benefit issues in spotlight amid RBNZ review

Commentators raise cost-benefit concerns over the RBNZ's capital settings review.

ANZ first bank to react to OCR cut
Economy

ANZ first bank to react to OCR cut

ANZ is the first bank to react after the Reserve Bank’s 50-basis-point official cash rate cut on Wednesday.“Lower interest rates are helping, and more and more customers are seeing the benefit of rate cuts,” Grant Knuckey, a managing director at ANZ, said.“We’ve ... [seen] people...

Staff reporters 08 Oct 2025
RBNZ cuts to 2.5% with more on the table
Economy

RBNZ cuts to 2.5% with more on the table

The committee remains open to further reductions, it said. 

Rebecca Howard 08 Oct 2025
RBNZ cuts OCR to 2.5%
Economy

RBNZ cuts OCR to 2.5%

RBNZ says its open to cutting more if necessary. 

Rebecca Howard 08 Oct 2025